Sandra Rojas-Caro is the chief medical officer of Gemini Therapeutics. She brings more than 20 years of broad-based research and clinical development experience across all phases of drug development, including successful global submissions, applied technology and translational biology environments.
She was previously chief medical officer for Aeglea Biotherapeutics, a biotechnology company developing enzyme-based therapeutics to treat rare diseases and cancer. Prior to Aeglea, Sandra served as group vice president of clinical research and development at Synageva BioPharma and, following the company’s acquisition by Alexion, vice president for the Metabolic Rare Diseases Unit. In this role, she helped lead the clinical development team that secured FDA approval of Kanuma for the treatment of lysosomal acid lipase deficiency. Prior to Alexion/Synageva, she held roles in clinical and translational research at Roche, Array BioPharma and Pfizer.
Sandra received her medical degree from the Pontifical Catholic University of Chile.